Comparative statistical analysis of osteoporosis treatment based on Hungarian claims data and interpretation of the results in respect to cost-effectiveness

被引:7
作者
Lakatos, P. [1 ]
Toth, E. [2 ]
Szekeres, L. [3 ]
Poor, G. [3 ]
Hejj, G. [3 ]
Marton, I. [4 ]
Takacs, I. [1 ]
机构
[1] Semmelweis Univ, Dept Med 1, H-1083 Budapest, Hungary
[2] Healthware Consulting Ltd, Budapest, Hungary
[3] Natl Inst Rheumatism & Physiotherapy, Budapest, Hungary
[4] Hungarian Soc Osteoporosis & Osteoarthrol, Budapest, Hungary
关键词
Cost-effectiveness; Fractures; Hospitalization; Osteoporosis; Treatment; HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; VERTEBRAL FRACTURES; NONVERTEBRAL FRACTURES; STRONTIUM RANELATE; PROPENSITY SCORE; RANDOMIZED-TRIAL; WOMEN; RISK; EPIDEMIOLOGY;
D O I
10.1007/s00198-014-2733-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The efficacy of interventions used in real life for the treatment of osteoporosis has not been evaluated on a national basis. We analysed the database of the single Hungarian health care provider between 2004 and 2010. A marked reduction in fracture incidence and hospitalization was seen, which also proved to be cost-effective. Osteoporosis and its consequences place a significant burden on the health care systems of developed countries. Present therapeutic modalities are effective in reducing the risk of fractures caused by osteoporosis. However, we do not know whether the interventions introduced in the past 15 years have significantly reduced the number of osteoporotic fractures in real life, and if yes, how cost-effectively. The database of the National Health Insurance Fund Administration in Hungary was analysed for the period between 2004 and 2010. Two specific patient groups were identified within the population. Patients, who were under osteoporosis treatment in more than 80 % of the potential treatment days in three consecutive years (patients with high compliance), were compared with patients where this ratio was under 20 % (patients with low compliance). Several statistical comparative models were implemented in order to capture a complete picture on the differences. Because of natural data heterogeneity of administration databases, propensity matching was applied as well. Comparing treated vs. control subjects, patients with high compliance showed a significant decrease in fracture risk and hospitalization, which was more robust after propensity adjustment. On the basis of the observed statistically significant differences, cost-effectiveness analysis was implemented. Utility loss due the observed fractures was compared with the total cost differences of the two arms based on modelling. Our calculations proved the cost-effectiveness of the long-term high compliance in real world settings. Our findings infer that the standardized and uniform health care of osteoporotic patients in a country may reduce general fracture incidence and hospitalization in a cost-effective way.
引用
收藏
页码:2077 / 2087
页数:11
相关论文
共 50 条
  • [31] AI-based opportunistic CT screening of incidental cardiovascular disease, osteoporosis, and sarcopenia: cost-effectiveness analysis
    Pickhardt, Perry J.
    Correale, Loredana
    Hassan, Cesare
    ABDOMINAL RADIOLOGY, 2023, 48 (03) : 1181 - 1198
  • [32] Efficient diagnosis and treatment of acute paracetamol poisoning: cost-effectiveness analysis of approaches based on a hospital toxicovigilance program
    Munoz Romo, Raul
    Borobia Perez, Alberto M.
    Munoz, Mario A.
    Carballo Cardona, Cesar
    Cobo Mora, Julio
    Carcas Sansuan, Antonio J.
    EMERGENCIAS, 2018, 30 (03): : 169 - 176
  • [33] Shortened Tuberculosis Treatment for People with HIV in South Africa A Model-based Evaluation and Cost-effectiveness Analysis
    Reddy, Krishna P.
    Horsburgh, C. Robert
    Wood, Robin
    Fields, Naomi F.
    Girouard, Michael P.
    Costantini, Sydney
    Hou, Taige
    Freedberg, Kenneth A.
    Walensky, Rochelle P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2020, 17 (02) : 202 - 211
  • [34] Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study
    Blommestein, Hedwig M.
    Issa, Djamila E.
    Pompen, Marjolein
    Ten Hoor, Gerhard
    Hogendoorn, Mels
    Joosten, Peter
    Zweegman, Sonja
    Huijgens, Peter C.
    Uyl-de Groot, Carin A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 92 (05) : 398 - 406
  • [35] Cost-effectiveness analysis of fosnetupitant in patients receiving cisplatin in Japan: analysis based on real-world data
    Inano, Hiroshi
    Morimoto, Yoshihito
    Kitagawa, Kanata
    Shibuya, Akito
    Nakagomi, Kozue
    Ota, Tomohiro
    Anzo, Yuri
    Miyauchi, Rika
    Shono, Aiko
    Watanabe, Kazuhiro
    Otori, Katsuya
    SUPPORTIVE CARE IN CANCER, 2025, 33 (02)
  • [36] Triage of Persons With Tuberculosis Symptoms Using Artificial Intelligence-Based Chest Radiograph Interpretation: A Cost-Effectiveness Analysis
    Nsengiyumva, Ntwali Placide
    Hussain, Hamidah
    Oxlade, Olivia
    Majidulla, Arman
    Nazish, Ahsana
    Khan, Aamir J.
    Menzies, Dick
    Khan, Faiz Ahmad
    Schwartzman, Kevin
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (12):
  • [37] Function After Spinal Treatment, Exercise, and Rehabilitation Cost-Effectiveness Analysis Based on a Randomized Controlled Trial
    Morris, Stephen
    Morris, Tim P.
    McGregor, Alison H.
    Dore, Caroline J.
    Jamrozik, Konrad
    SPINE, 2011, 36 (21) : 1807 - 1814
  • [38] Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan (vol 28, pg 1939, 2017)
    Moriwaki, K.
    Mouri, M.
    Hagino, H.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (06) : 1951 - 1952
  • [39] Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate
    Tomohiro Yoshizawa
    Tomofumi Nishino
    Ichiro Okubo
    Masashi Yamazaki
    Archives of Osteoporosis, 2018, 13
  • [40] Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
    Le, Quang A.
    Hay, Joel W.
    Becker, Russell
    Wang, Yamei
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 134 - 143